Pharma value capture threatens Yazen
Yazen
The strategic risk is that medication access is turning into a low margin utility, which means Yazen has to win on care outcomes, retention, and employer or insurer distribution rather than on being the easiest place to get GLP-1s. Yazen charges about €90 per month for coaching, clinician access, and the app, while patients buy drugs separately, so if Novo Nordisk and Eli Lilly make branded supply easy and predictable at $499, the part of the journey that still carries pricing power is the care layer around the drug.
-
Yazen is already structured like a care layer on top of pharma. Its workflow is screening, nurse consult, lab kit, physician review, prescription routing to partner pharmacies, then ongoing messaging with coaches and clinicians. That makes it less exposed than a pure prescription broker, but it also means the subscription has to justify itself on adherence and results, not drug access.
-
The broader market is already moving this way. Lilly expanded Zepbound self pay vial pricing to $499 or less in 2025, and NovoCare offered Wegovy at $499 for self pay patients. In the U.S., platforms like Ro increasingly pipe prescriptions into manufacturer channels behind the scenes, which shows how telehealth brands can keep the front end while losing economics on fulfillment.
-
Scaled rivals have more room to absorb this squeeze. Ro built owned labs, pharmacies, and home testing into its obesity workflow, and Numan reached about $90M of revenue in 2024 across a broader telehealth base. By contrast, Yazen was about $17.3M in 2024 revenue and focused mainly on obesity, so it has less diversification if GLP-1 access becomes standardized across Europe.
The next phase of competition shifts from who can source the drug to who can keep patients engaged for 12 to 24 months, prove durable weight loss, and sell that program into employers, insurers, and public systems. That is why Yazen's maintenance tier, connected device data, and B2B channel matter more over time than the prescription itself.